Intravenous dolasetron and ondansetron in prevention of postoperative nausea and vomiting: A multicenter, double-blind, placebo-controlled study

Acta Anaesthesiologica Scandinavica

Volumn 41, Issue 7, 1997, Pages 914-922

  Korttila, K ^a   Clergue, F ^b   Leeser, J ^c   Feiss, P ^d   Olthoff, D ^e   Payeur Michel, C ^f   Wessel, P ^g   Nave, S ^h   Hahne, W ⁱ   Brown, R ⁱ  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HÔPITAL TENON   (France)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^d DUPUYTREN UNIVERSITY HOSPITAL   (France)

^e Klinik für Anaesthesiologie   (Germany)

^f Hopital du Hasenrain CH de Mulhouse   (France)

^g HÔTEL DIEU   (France)

^h Hoechst Marion Roussel ^*

ⁱ SANOFI   (France)

Author keywords

Emesis; Intravenous dolasetron mesilate; Intravenous ondansetron; Postoperative nausea and vomiting; Prevention

Indexed keywords

ANESTHETIC AGENT; DOLASETRON MESILATE; ONDANSETRON; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

EID: 8544267918     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.1997.tb04809.x     Document Type: Article

References (33)

1. Korttila K. Recovery from outpatient anesthesia. Factors affecting outcome. Anaesthesia 1995: 50(suppl): 22-28.
2. Watcha MF, White PF. Post-operative nausea and vomiting: do they matter? Eur J Anaesth 1995: 12(suppl 10): 18-23.
3. Gold BS, Kitz DS, Lecky JH, Neuhaus JM. Unanticipated admission to the hospital following ambulatory surgery. JAMA 1989: 262 (21): 3008-3010
4. Kenny GNC. Risk factors for postoperative nausea and vomiting. Anaesthesia 1994: 49(suppl): 6-10.
5. Mathia WJ, Bell SK, Leak WD. Effect of preoperative metoclopramide and droperidol on postoperative nausea and vomiting in ambulatory surgery patients. J Am Assoc Nurse Anesth 1988: 56(4): 325-333.
6. Uppington J, Dunnet J, Blogg CE. Transdermal hyoscine and postoperative nausea and vomiting. Anaesthesia 1986; 41: 16-20.
7. Korttila K, Linnoila M. Skills related to driving after intravenous diazepam, flunitrazepam or droperidol. Br J Anaesth 1974: 46: 961-969.
8. DiGrandi T, Simon J. Promethazine-induced dystonic reactions. Pediatr Emerg Care 1987: 3: 91-92.
9. Melnick B. Extrapyramidal reactions to low-dose droperidol. Anesthesiology 1988: 69: 424-426.
10. Rothenberg DM, Parnass SM, Litwack K, McCarthy RJ, Newman LM. Efficacy of ephedrine in the prevention of postoperative nausea and vomiting. Anesth Analg 1991: 72: 58-61.
11. McKenzie R, Kovac A, O'Connor T, Duncalf D, Angel J, Gratz I, et al. Comparison of ondansetron versus placebo to prevent postoperative nausea and vomiting in women undergoing ambulatory gynecologic surgery. Anesthesiology 1993: 78: 21-28.
12. 3 antagonist ondansetron. Anesthesiology 1993: 78: 15-20.
13. Mikawa K, Takao Y, Nishina K, Maekawa N, Obara H. The antiemetic efficacy of prophylactic granisetron in gynecologic surgery. Anesth Analg 1995: 80: 970-974.
14. Melson T, Graczyk SG, Hickok C, McKenzie R, Kallar S. Prevention of nausea and vomiting with dolasetron after outpatient laparoscopic surgery. Anesthesiology 1995: 83(3A). (Abstract A7)
15. Diemunsch P, Nave S, Meyerson LJ. Evaluation of the antiemetic properties of dolasetron mesilate in gynecological surgery. Br J Anaesth 1994: 72: 82. (Abstract A159)
16. Diemunsch P, Leeser J, Feiss P, D'Hollander A, Bradburn BG, Paxton D, et al. Dolasetron mesilate treats established nausea and vomiting after general surgery. Anesthesiology 1995: 83(3A). (Abstract A1109)
17. Kovac A, Melson T, Graczyk S, Scuderi P, Watkins WD, MCPR44 Study Group. Treatment of postoperative nausea and vomiting with single doses of IV dolasetron: a multicenter trial. Anesthesiology 1995: 83(3A). (Abstract A6)
18. 3 receptor antagonist. Drug Dev Res 1995: 34: 289-296.
19. 3 antagonists MDL 73147EF (dolasetron mesylate) and MDL 74156 in NG108-15 neuroblastoma x glioma cells. Eur J Pharmacol 1992: 219: 9-13.
20. 3 receptors. Drug Dev Res 1993: 28: 87-93.
21. Kris MG, Grunberg SM, Gralla RJ, Baltzer L, Zaretsky SA, Lifsey D, et al. Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin. J Clin Oncol 1994: 12: 1045-1049.
22. 3 antagonist, in cancer patients treated with cisplatin. Am J Clin Oncol 1994: 17: 97-102.
23. Hesketh PJ, Gandara DR, Hesketh AM, Facada A, Perez EA, Webber LM, et al. Dose ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin and cyclophosphamide. Support Care Cancer 1996: 4: 141-146.
24. Audhuy B, Cappelaere P, Martin M, Cervanrtes A, Fabbro M, Riviere A, et al. A double-blind, randomized comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high-dose cisplatin chemotherapy. Eur J Cancer 1996: 32A(5): 807-813.
25. Dershwitz M. Antiemetic drugs. In: White P, ed. Ambulatory anesthesia and surgery. London: Saunders, 1997: 441-453.
26. Watcha MF. Cost minimization, cost-benefit, and cost-utility analyses. In: White P, ed. Ambulatory anesthesia and surgery. London: Saunders, 1997: 648-672.
27. Korttila K. The study of postoperative nausea and vomiting. Br J Anaesth 1992: 69(suppl 1): 20S-23S.
28. Watcha MF, White PF. Postoperative nausea and vomiting, its etiology, treatment, and prevention. Anesthesiology 1992: 27: 162-184.
29. Palazzo MGA, Strunin L. Anesthesia and emesis. I. Etiology. Can Anaesth Soc J 1984: 31(2): 178-187.
30. Fisher DM. Surrogate endpoints: Are they meaningful? Anesthesiology 1994: 81: 795-796. (Editorial)
31. Madej TH, Simpson KH. Comparison of the use of domperidone, droperidol and metoclopramide in the prevention of nausea and vomiting after gynaecological surgery. Br J Anaesth 1986: 58: 879-883.
32. Baltzer L, Kris MG, Hinkley L, Pisters KMW, Lacava PV, Pierri MK, et al. Reversible electrocardiographic interval prolongations following the specific serotonin antagonists ondansetron (OND) and dolasetron mesylate (DM): a possible drug effect without sequelae? Proc Am Soc Clin Oncol 1994: 13: 433. (Abstract)
33. Lifsey DS, Gralla RJ, Clark RA, Kline RC. Electrocardiographic changes with serotonin antagonist antiemetics: rate of occurrence and clinical relevance Proc Am Soc Clin Oncol 1993: 12: 463. (Abstract)